Australia ARTG Sponsor Map: Who Controls Market Access for 63,000 Devices?

Executive Summary

Australia's Therapeutic Goods Administration (TGA) requires every medical device supplied in the country to be included in the Australian Register of Therapeutic Goods (ARTG). The sponsor — an Australian entity — holds the ARTG entry and carries legal responsibility for post-market compliance, adverse event reporting, and communication with the TGA.

Our analysis of the complete ARTG medical device dataset (extracted 5 June 2026) reveals a highly concentrated sponsor landscape: 3,377 sponsors manage 63,131 medical device listings, but just 10 sponsors control 21.6% of all listings, and 34.9% of sponsors hold only a single entry. One sponsor — Emergo Australia — represents 375 different overseas manufacturers, making it a critical gateway for international device companies entering the Australian market.

This article presents the data, the concentration dynamics, and practical implications for manufacturers evaluating sponsor due diligence.

Data Source and Method

• Source: Australian Register of Therapeutic Goods (ARTG), public extract via TGA compliance database
• Analysis sample: ARTG public extract dated 5 June 2026 (99,408 rows total)
• Scope: 63,131 entries with therapeutic_type = "Medical Device" (excludes medicines, biologicals, and other therapeutic goods)
• Analysis date: 6 June 2026
• Computed using: MedDeviceGuide analysis of the ARTG public extract

The ARTG at a Glance

The dataset is dominated by the standard "Included" category, which permits domestic supply. IVD-specific listings account for less than 5% of total medical device entries.

Top Sponsors by Listing Count

The top 20 sponsors by ARTG listing count are dominated by large orthopaedic, cardiovascular, and imaging multinationals operating through Australian subsidiaries:

Key insight: The top 10 sponsors control 13,613 out of 63,131 listings (21.6%). The top 20 control 28.8%. This is not unusual for a mature regulatory market — large companies acquire multiple brands, each with its own ARTG entries, and distribution-focused sponsors aggregate product portfolios from dozens of manufacturers.

The Manufacturer Gateway: Which Sponsors Represent the Most Overseas Manufacturers?

Listing count alone does not reveal the most important dimension of sponsor influence: how many different overseas manufacturers a sponsor represents. This metric matters because each manufacturer brings distinct quality system evidence, conformity assessment documentation, and post-market obligations.

Emergo Australia (part of UL Solutions) stands apart. With 375 unique manufacturers represented, it is the single largest aggregation point for overseas medical device manufacturers seeking Australian market access. Device Technologies Australia (235 manufacturers) and Life Healthcare (218) are the next-largest multi-manufacturer sponsors.

This structure means that sponsor selection for Australian market entry is not just a commercial decision — it is a regulatory concentration decision. If a sponsor like Emergo were to cease operations, the TGA would need to transfer hundreds of ARTG entries to new sponsors, creating disruption for the affected manufacturers.

Sponsor Concentration Curve

The concentration curve below shows how quickly the cumulative share of listings rises as sponsors are added from largest to smallest:

• ~200 sponsors control 50% of all listings
• ~800 sponsors control 80% of all listings
• The remaining ~2,500 sponsors share the bottom 20%

Listings by Start Year

The ARTG shows accelerating growth in new listings since the mid-2010s, with a sharp increase in 2024–2026:

The 2024–2026 surge (12,392 new entries in roughly 2.5 years) suggests that either a large volume of new devices is entering the Australian market, or existing sponsors are significantly expanding their registered portfolios — possibly driven by EU MDR transition pressures pushing manufacturers to diversify into non-EU markets.

Emergo Deep Dive: What Does the Largest Multi-Manufacturer Sponsor Look Like?

Emergo Australia's 1,354 ARTG listings span 375 distinct manufacturers. The top manufacturers under Emergo's sponsorship include a mix of US, European, and Asian device companies — typically small-to-mid-size firms that outsource Australian regulatory representation rather than establishing their own local subsidiary.

Sponsor Portfolio Size Distribution

Over one-third of sponsors hold exactly one ARTG entry. These single-entry sponsors are often small manufacturers registering their own product, or local distributors carrying a single imported device line. At the other extreme, just 9 sponsors each hold more than 500 listings.

Practical Implications for Manufacturers

1. Sponsor Due Diligence Is a Regulatory Risk Decision

For overseas manufacturers, choosing a sponsor is not a formality — it is a long-term regulatory partnership. Under the Therapeutic Goods Act 1989 and TGA guidance, the sponsor is legally responsible for holding the ARTG entry, post-market reporting, and acting as the TGA's point of contact. If the sponsor fails, the manufacturer must arrange a sponsor transfer, which requires full re-notification to the TGA and can interrupt market supply.

2. Concentration Risk

The dominance of a small number of multi-manufacturer sponsors (Emergo: 375 manufacturers; Device Technologies: 235) creates systemic concentration risk. Manufacturers should evaluate:

• Does the sponsor have the operational capacity to manage hundreds of manufacturers' compliance obligations?
• What is the sponsor's financial stability and succession plan?
• What happens to your ARTG entries if the sponsor merges, is acquired, or exits the market?

3. Single-Entry Sponsors and the Long Tail

1,180 sponsors (34.9%) hold only one listing. These "long-tail" sponsors may be:

• Australian subsidiaries of a single overseas manufacturer
• Small distributors with one product line
• Startups with an initial device registration

For manufacturers considering a small or single-entry sponsor, the risk is that the sponsor may lack the infrastructure to handle adverse event reporting, recall coordination, or TGA audits effectively.

4. Recent Growth Signals Market Pressure

The 12,392 new listings added since 2024 suggest significant market entry activity. Manufacturers entering Australia now should expect a competitive sponsor market and should begin sponsor evaluation early in their regulatory planning.

Method Notes

• All figures are computed directly from the ARTG public extract dated 5 June 2026.
• The analysis counts ARTG entries (rows), not unique device identifiers. Some devices may have multiple entries (e.g., different GMDN codes, variants, or export-only listings).
• Manufacturer names are as recorded in the ARTG. Some manufacturers may appear under variant names.
• "Sponsor" refers to the entity listed as the ARTG sponsor, which may be a local subsidiary, an independent regulatory representative, or a distributor.

Sources

• ARTG public database, Therapeutic Goods Administration (TGA), Australian Department of Health and Aged Care. Data extracted 5 June 2026.
• TGA guidance on importing and supplying medical devices in Australia.
• Therapeutic Goods Act 1989 (Cth), particularly provisions relating to sponsor responsibilities and ARTG inclusion.
• MedDeviceGuide analysis of the ARTG public extract, run date 6 June 2026.